ERS Research Seminar

IPF and cancer: wounds that do not heal

13 – 14 February 2015 – Athens, Greece (Scientific Programme as of October 27, 2014)

Friday, 13 February 2015 - Research Day

08:30 – 08:45 Registration

08:45 – 09:00 Welcome and introduction, K. Antoniou, V. Poletti

SESSION 1: Are IPF and cancer twin diseases? A biological point of view

Session 1.a: Chairs: M. Chilosi, V. Poletti

09:00 – 09:30 Similarities and links between IPF and cancer: biologic considerations – C. Vancheri

09:30 – 10:00 Epigenetics in IPF and lung cancer – K. Antoniou

10:00 – 10:30 Round table and questions; Discussants – M. Chilosi, V. Poletti

10:30 – 11:00 *Coffee break*

Session 1.b: Chairs: C.Vancheri, T. Sethi

11:00 – 11:30 Epithelial proliferative pathways in IPF – O. Eickelberg

11:30 – 12:00 Myofibroblast origin and behaviour in IPF – B. Crestani

12:00 – 12:30 Angiogenesis in IPF and lung Cancer: a common pathway? – M. Kolb

12:30 – 13:00 Round table and questions; Discussants – C. Vancheri, T. Sethi

13:00 - 14:30 Lunch break

Session 1.c: Chairs: K. Antoniou, B. Crestani

14:30 – 15:00 Oncogene induced senescence in cancer and IPF – M. Chilosi

15:00 – 15:30 The role of stem cells in IPF – G. Margaritopoulos

15:30 – 16:00 The role of stem cells in cancer – T. Sethi
16:00 – 16:30 Round table and questions; Discussants – K. Antoniou, B. Crestani
16:30 – 17:00 Discussion

Saturday, 14 February 2015 - Clinical day

Session 2: Are IPF and cancer twin diseases? A clinical point of view

Chairs: A. Wells, V. Poletti

08:30-09:00 Epidemiology, clinical, imaging and histology aspects of lung cancer in IPF – V. Poletti

09:00 – 09:30 Lung cancer and other ILDs – D. Bouros

09:30 – 10:00 Round table and questions; Discussants – A. Wells, V. Poletti

10:00 – 10:30 *Coffee break*

Session 3: Treatment issues

Chairs: D. Bouros, J. Cadranel

10:30 – 11:00 Endpoints in IPF and lung cancer trials: controversies and perspectives – A. Wells

11:00 – 11:30 How to treat lung cancer in IPF patients – J. Cadranel

11:30 – 12.00 Common therapeutic approaches in IPF and lung cancer – M. Kreuter

12:00 – 13:00 Lunch break

13:00 – 14:00 Round table and discussion; Discussants – D. Bouros, J. Cadranel

14:00 Discussion and closing remarks – V. Poletti, K. Antoniou